Biosimilars Deals 2018 Archives

Xbrane and STADA expand biosimilar development partnership

May 31, 2019

Xbrane and STADA announce expansion of biosimilar development partnership. This expansion will now include the development of Xbrane’s biosimilar candidates certolizumab pegol and nivolumab, as well as other biosimilars.

Sandoz enters commercialisation agreement with Gan & Lee Pharmaceutical

Dec 28, 2018

Sandoz announces agreement with Gan & Lee Pharmaceutical to commercialise biosimilar insulins.

Fuji Pharma announces acquisition of stake in Alvotech

Dec 22, 2018

Fuji Pharma announces acquisition of 4.2% stake in Alvotech for roughly $50 million.

Fuji Pharma and Alvotech enter exclusive partnership agreement to commercialise biosimilars

Nov 19, 2018

Fuji Pharma and Alvotech announce exclusive partnership agreement for the commercialisation of Alvotech’s biosimilars in Japan. Fuji Pharma will be responsible for the registration and commercialisation of products, while Alvotech will be responsible for development and supply.

Biogen and Samsung Bioepis close asset transfer for Biogen share increase

Nov 7, 2018

Biogen and Samsung Bioepis close asset transfer to increase Biogen’s share in Samsung Bioepis to 49.9%. This deal originates from the initial creation of Samsung Bioepis and the partnership between Biogen and Samsung BioLogics, in which Biogen was granted an option to increase its share in the company, expiring in mid 2018.

Munidpharma acquires Cinfa Biotech

Oct 10, 2018

Munidpharma acquires Cinfa Biotech, gaining immediate access to pegfilgrastim biosimilar and a platform to potentially develop more biosimilars in the future.

Merck secures development deal to supply rituximab biosimilar

Oct 7, 2018

Merck secures 5 year, $117.5M deal with US Department of Veterans Affairs to supply rituximab biosimilar developed by Samsung.

US-Mexico-Canada Agreement exclusivity period raises concerns

Oct 3, 2018

US-Mexico-Canada Agreement includes 10 year exclusivity period for biologic drugs, raising concerns that competition will be hindered to the disadvantage of consumers and health services in those regions. Currently the exclusivity period stands at 8 years in Canada and 5 years in Mexico.

iBio and CC-Pharming enter marketing agreement

Aug 7, 2018

iBio and CC-Pharming enter agreement to develop biosimilar rituxumab for the Chinese market.

Catalent announces development and manufacture collaboration with Valerius

May 15, 2018

Catalent announced a collaboration for the development and manufacture of Valerius’ biosimilar products. Catalent will provide cell line development and support cGMP manufacturing activities from Phase 1 through to commercial stages from the USA.

Speculation into potential biosimilars JV in Malaysia

Mar 29, 2018

Although details have not been announced by the companies, it appears that Korea’s Alteogen, and Malaysia’s Inno Bio Ventures are setting up a biosimilars JV in Malaysia, with an ASEAN focus. Read more

BioSciences Corp and Mab-Venture announce development/commercialisation deal

Feb 10, 2018

Californian HQ’d BioSciences Corp & Shanghai based Mab-Venture announce a deal under which Mab-Venture will develop and manufacture biosimilars and BioSciences Corp will commercialise (through partners) those products in India, SAARC, MENA, Turkey, LatAm and Russia. The deal covers “multiple” products which have not been named. Read more

Sandoz and Biocon announce collaboration for commercialisation of biosimilar medicines

Jan 18, 2018

Sandoz and Biocon announce a collaboration to develop and commercialise multiple biosimilar medicines. The companies will share responsibility for development, manufacturing and regulatory approvals. Sandoz is responsible for leading commercialisation in the US & EU, while Biocon will lead commercialisation efforts in the rest of the world.